Shilin Xu

1.5k total citations
69 papers, 1.0k citations indexed

About

Shilin Xu is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Shilin Xu has authored 69 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Molecular Biology, 17 papers in Oncology and 10 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Shilin Xu's work include Protein Degradation and Inhibitors (8 papers), Ubiquitin and proteasome pathways (6 papers) and Cancer therapeutics and mechanisms (6 papers). Shilin Xu is often cited by papers focused on Protein Degradation and Inhibitors (8 papers), Ubiquitin and proteasome pathways (6 papers) and Cancer therapeutics and mechanisms (6 papers). Shilin Xu collaborates with scholars based in China, United States and United Kingdom. Shilin Xu's co-authors include Yuyang Tian, Lumei Kang, Hongping Chen, Yingxue Liu, Lianwen Zhang, Xiaomei Ren, Tianfeng Xu, Ke Ding, Zhang Zhang and Shaomeng Wang and has published in prestigious journals such as Angewandte Chemie International Edition, SHILAP Revista de lepidopterología and Journal of Hazardous Materials.

In The Last Decade

Shilin Xu

65 papers receiving 997 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Shilin Xu China 18 538 265 155 125 86 69 1.0k
Lu Dai China 21 570 1.1× 147 0.6× 295 1.9× 99 0.8× 153 1.8× 74 1.3k
Yue‐Lei Chen China 20 596 1.1× 139 0.5× 189 1.2× 52 0.4× 63 0.7× 62 1.0k
Xiaofei Zhou United States 20 431 0.8× 455 1.7× 63 0.4× 109 0.9× 69 0.8× 79 1.2k
Elena Porcù Italy 19 432 0.8× 156 0.6× 284 1.8× 33 0.3× 70 0.8× 39 901
Émilie Mathieu France 15 223 0.4× 160 0.6× 101 0.7× 60 0.5× 62 0.7× 28 874
Shanshan Li China 18 544 1.0× 169 0.6× 54 0.3× 79 0.6× 49 0.6× 49 1.0k
Shuang Ding China 21 438 0.8× 122 0.5× 47 0.3× 81 0.6× 61 0.7× 88 983
Monica Lupi Italy 24 913 1.7× 332 1.3× 151 1.0× 95 0.8× 50 0.6× 67 1.5k
Anke G. Roth Germany 12 840 1.6× 241 0.9× 96 0.6× 49 0.4× 104 1.2× 14 1.1k
Ahmed F. Salem United States 21 799 1.5× 249 0.9× 186 1.2× 53 0.4× 24 0.3× 42 1.2k

Countries citing papers authored by Shilin Xu

Since Specialization
Citations

This map shows the geographic impact of Shilin Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shilin Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shilin Xu more than expected).

Fields of papers citing papers by Shilin Xu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shilin Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shilin Xu. The network helps show where Shilin Xu may publish in the future.

Co-authorship network of co-authors of Shilin Xu

This figure shows the co-authorship network connecting the top 25 collaborators of Shilin Xu. A scholar is included among the top collaborators of Shilin Xu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shilin Xu. Shilin Xu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Chen, Zhiwen, Yaoliang Sun, Lijie Peng, et al.. (2025). Discovery of a first-in-class PROTAC degrader of histone lysine demethylase KDM4. European Journal of Medicinal Chemistry. 288. 117410–117410. 4 indexed citations
2.
Wang, Jia, Youben Fan, Shilin Xu, et al.. (2025). Self-propelled biomotors co-deliver doxorubicin liposomes and aPD-1 antibody to fight breast cancer. Chinese Chemical Letters. 37(2). 111607–111607. 1 indexed citations
3.
Lin, Liang‐In, Yaoliang Sun, Rongrong Cui, et al.. (2025). Furo[2,3- f ]quinazolin-7(6 H )-one Derivatives as Potent, Selective, and Orally Bioavailable MAT2A Inhibitors for MTAP-Deficient Cancer Therapy. Journal of Medicinal Chemistry. 68(22). 24213–24231.
4.
Xu, Shilin, et al.. (2025). Application of machine learning in the study of heavy metal remediation in soil using biochar-based nanocomposites. Next Materials. 9. 101261–101261. 1 indexed citations
5.
Wu, Meixuan, Jiani Yang, Yaqian Zhao, et al.. (2024). Comprehensive machine learning-based preoperative blood features predict the prognosis for ovarian cancer. BMC Cancer. 24(1). 267–267. 4 indexed citations
6.
Yang, Jiani, Yue Zhang, Shanshan Cheng, et al.. (2024). Anoikis-related signature predicts prognosis and characterizes immune landscape of ovarian cancer. Cancer Cell International. 24(1). 53–53. 5 indexed citations
7.
8.
Li, Xuguang, Shilin Xu, Xuemei Li, et al.. (2024). Novel insight into the genetic signatures of altitude adaptation related body composition in Tibetans. Frontiers in Public Health. 12. 1355659–1355659. 4 indexed citations
9.
Liu, Yifeng, et al.. (2023). Tight gas accumulation caused by overpressure: Insights from three-dimensional seismic data in the western Sichuan Basin, southwest China. Geoenergy Science and Engineering. 223. 211589–211589. 7 indexed citations
10.
Chen, Miao, et al.. (2023). A label-free dually-amplified aptamer sensor for the specific detection of amyloid-beta peptide oligomers in cerebrospinal fluids. Analytica Chimica Acta. 1266. 341298–341298. 13 indexed citations
11.
Ma, Mingjun, Chao Wang, Meixuan Wu, et al.. (2023). CSGALNACT2 restricts ovarian cancer migration and invasion by modulating MAPK/ERK pathway through DUSP1. Cellular Oncology. 47(3). 897–915. 7 indexed citations
12.
Xu, Shilin, et al.. (2023). Clinical application of PARP inhibitors in ovarian cancer: from molecular mechanisms to the current status. Journal of Ovarian Research. 16(1). 6–6. 28 indexed citations
13.
Xu, Shilin, et al.. (2023). Capsaicin alleviates neuronal apoptosis and schizophrenia-like behavioral abnormalities induced by early life stress. SHILAP Revista de lepidopterología. 9(1). 77–77. 9 indexed citations
14.
Zhang, Minghai, Yingjie Wang, Shilin Xu, et al.. (2023). Endoplasmic Reticulum Stress-Related Ten-Biomarker Risk Classifier for Survival Evaluation in Epithelial Ovarian Cancer and TRPM2: A Potential Therapeutic Target of Ovarian Cancer. International Journal of Molecular Sciences. 24(18). 14010–14010. 4 indexed citations
15.
Yang, Jiani, et al.. (2023). A novel autophagy-related gene signature associated with prognosis and immune microenvironment in ovarian cancer. Journal of Ovarian Research. 16(1). 86–86. 7 indexed citations
16.
Xu, Shilin, Xiaocui Fang, Haiyan Xing, et al.. (2022). CD123 Antagonistic Peptides Assembled with Nanomicelles Act as Monotherapeutics to Combat Refractory Acute Myeloid Leukemia. ACS Applied Materials & Interfaces. 14(34). 38584–38593. 5 indexed citations
17.
Hu, Nan, Fangyang Wang, Tianyu Sun, et al.. (2021). Follicular Lymphoma–associated BTK Mutations are Inactivating Resulting in Augmented AKT Activation. Clinical Cancer Research. 27(8). 2301–2313. 19 indexed citations
18.
Li, Heng, Xuelian Ren, Yaoliang Sun, et al.. (2021). Discovery of a potent, selective, and covalent ZAP-70 kinase inhibitor. European Journal of Medicinal Chemistry. 219. 113393–113393. 8 indexed citations
19.
Zhang, Kaiyue, Xiaocui Fang, Qing You, et al.. (2020). Novel peptide-directed liposomes for targeted combination therapy of breast tumors. Materials Advances. 1(9). 3483–3495. 3 indexed citations
20.
Xu, Shilin, Angelo Aguilar, Tianfeng Xu, et al.. (2017). Design of the First‐in‐Class, Highly Potent Irreversible Inhibitor Targeting the Menin‐MLL Protein–Protein Interaction. Angewandte Chemie International Edition. 57(6). 1601–1605. 51 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Lu Dai Breakdown of academic impact, for papers by Yue‐Lei Chen Breakdown of academic impact, for papers by Xiaofei Zhou Breakdown of academic impact, for papers by Elena Porcù Breakdown of academic impact, for papers by Émilie Mathieu Breakdown of academic impact, for papers by Shanshan Li Breakdown of academic impact, for papers by Shuang Ding Breakdown of academic impact, for papers by Monica Lupi Breakdown of academic impact, for papers by Anke G. Roth Breakdown of academic impact, for papers by Ahmed F. Salem
Rankless by CCL
2026